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ABSTRACT
In order to boost the identification of low-molecular-
weight drugs on protein–protein interactions (PPI), it
is essential to properly collect and annotate exper-
imental data about successful examples. This pro-
vides the scientific community with the necessary
information to derive trends about privileged physic-
ochemical properties and chemotypes that maximize
the likelihood of promoting a given chemical probe
to the most advanced stages of development. To
this end we have developed iPPI-DB (freely accessi-
ble at http://www.ippidb.cdithem.fr), a database that
contains the structure, some physicochemical char-
acteristics, the pharmacological data and the pro-
file of the PPI targets of several hundreds mod-
ulators of protein–protein interactions. iPPI-DB is
accessible through a web application and can be
queried according to two general approaches: us-
ing physicochemical/pharmacological criteria; or by
chemical similarity to a user-defined structure in-
put. In both cases the results are displayed as a
sortable and exportable datasheet with links to ex-
ternal databases such as Uniprot, PubMed. Further-
more each compound in the table has a link to an
individual ID card that contains its physicochemi-
cal and pharmacological profile derived from iPPI-
DB data. This includes information about its binding
data, ligand and lipophilic efficiencies, location in the
PPI chemical space, and importantly similarity with
known drugs, and links to external databases like
PubChem, and ChEMBL.
INTRODUCTION
Drug discovery is a remarkably complicated process and
among the many hurdles that drug hunters have to face
is the paucity of targets. The focus of these past 50 years
has thus been centered on certain large enzyme families, ion
channels and/or receptors because they were deemed more
amenable to modulation by low molecular weight (LMW)
compounds (1–3). These observations stand in sharp con-
trast to the large number of mainly untapped protein–
protein interactions (PPI). PPIs play an essential role in
nearly all biological processes and their deregulation is of-
ten associated with disease states. For this reason, there is
a growing interest to target them for therapeutic interven-
tions using LMW compounds (<1000 g/mol). Still, tar-
geting PPIs with LMW drugs remains one of the most
difficult challenges in molecular medicine. As opposed to
most traditional targets, PPIs have not evolved to bind
small molecules (4). Indeed, the molecular topography of
most known PPIs, often described as shallow, large and hy-
drophobic, makes them harder to tackle with small com-
pounds and these features have often been translated in the
design of larger and more hydrophobic modulators. In fact,
such interfaces are now known to preferentially bind com-
pounds that display some specific physicochemical charac-
teristics and chemotypes (5–7). Yet, analyzing further suc-
cessful LMW PPI modulators should be essential to ratio-
nalize what makes those molecules so special and capable
to bind to such intricate surfaces and thus assist the design
of future generations of PPI inhibitors. Two databases al-
ready propose to access the structural and pharmacolog-
ical data of existing successful examples of PPI modula-
tors. First, the TIMBAL (8) database proposes compounds
that are automatically imported from ChEMBL (9) (https:
//www.ebi.ac.uk/chembl/) following a manual selection of
the PPI target type, it contains the data of about 8900 com-
pounds on several PPI targets. Most of the data come from
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a large pool of integrins for which the target is not always
clearly identified. Second, the 2P2I-db (10) is a manually
curated database from the PDB (11) (Protein Data Bank)
that collects the crystallographic data of cocrystallized or-
thosteric PPI inhibitors. In the last version, it contains 242
compounds.
In order to help the scientific community to gain new
knowledge about LMWmodulators of this new target class,
we propose a database, named iPPI-DB, together with a
user-friendly web interface (http://www.ippidb.cdithem.fr).
The database is actually the second release of a previous ver-
sion of the database that was before password protected and
for which only a representative fraction of the compounds
were accessible. We have decided to nowmake the data fully
available to everyone while also adding new functionalities
(described below) (12), such as an embedded chemical sim-
ilarity search, a query toward drug candidates and the pos-
sibility to export all results as a CSV file.
RESULTS
Presentation of iPPI-DB
iPPI-DB is a relational database containing the structure,
the physicochemical characteristics, the pharmacological
data (biochemical and/or cellular binding data) of com-
pounds modulating known PPI targets as well as the pro-
file of the corresponding targets. As those data are man-
ually extracted from the literature and curated by experts,
we set up a comprehensive protocol to decide whether or
not a given compound should enter the database and thus
such as to ensure assure the data quality. First, we consider
only world patents and peer-reviewed articles from scientific
journals with expertise in medicinal chemistry. Also consid-
ered, the PPI targets must have been discussed in several
scientific publications with for instance links between bi-
ological studies previously published, therefore with some
demonstrating the pertinence of the interactions and their
contribution in a given disease state andmore specifically in
terms of functional mechanism. Moreover, only small non-
peptide compounds are selected such thatmetal-based com-
pounds, macrocycles andmolecules containing atoms other
than C, N, O, S, P and halogens are not currently included.
Furthermore, to be confident about the actual compound
activities, we have chosen to rule out assays containing only
percentage of inhibition and select compounds and assays
for which a dose-response study was carried out and led to
any of the following measures of activity: Kd, Ki, IC50 or
EC50. Regardless of the assay type, we also impose a 30
M threshold on that activity to prevent as much as pos-
sible adding non specific binders in the collection. A se-
ries of nine descriptors are calculated for each compound
using the Chemaxon JChem library v6.1 (www.chemaxon.
com). Those descriptors are commonly used to character-
ize the physicochemical profile of small molecules, namely
molecular weight, AlogP (13), number of Hydrogen bond
donors and acceptors, the topological polar surface area
(14), the number of rotatable bonds, the number of aro-
matic rings according to Ritchie (15), the proportion of sp3
carbon––Fsp3, and the number of chiral centers––R/S. At
this time, a total of 2461 binding data have been collected on
1650 compounds across 13 families of highly homologous
PPI targets. This represents a significantly higher number of
accessible data than in the first version, which only provided
access to a representative subset of 352 compounds. As de-
scribed below, the interface now allows the user to perform a
chemical similarity search on iPPI-DB, to restrict the search
only to drug candidates, and to export all results, which was
not available in the first version.
iPPI-DB webapps
In order for the PPI scientific community to fully make use
of the database, we have designed a new user-friendly web
application that offers tools and predictive models as well
as two approaches to query iPPI-DB. The first possibility to
search the database is to use physicochemical and pharma-
cological criteria on a given target. The second possibility
is to import an input molecule as the query compound and
search by chemical similarity the entire collection regardless
of their target type.
Querying iPPI-DB using physicochemical or pharmacologi-
cal criteria
In the first approach physicochemical and pharmacological
criteria can be defined to search active compounds within
iPPI-DB on a given PPI target. The user can refine the
search by tuning several properties such as potency thresh-
olds, physicochemical descriptors (e.g. molecular weight,
hydrophobicity, Fsp3). As an alternative, the user can ap-
ply one of the three commonly used physicochemical rules
namely Lipinski’s rule of five (16), Veber’s (17) and Pfizer’s
3/75 (18) in order to select only compounds that are pre-
dicted as orally bioavailable in humans, rats or as poten-
tially less toxic, respectively. Finally, the user can choose to
extract only drug candidates on the PPI targets that have
some compounds presently tested in preclinical or clinical
phases (annotated using the data MDDR march 2012).
Querying iPPI-DB using chemical similarity to a user-
defined compound
The second approach to query iPPI-DB is to use a com-
pound structure as an input and perform a chemical sim-
ilarity search between this compound and all the modula-
tors present in iPPI-DB. The user can either copy and paste
a SMILES string or sketch directly a molecule within the
Marvin JS editor (www.chemaxon.com) embedded in the
interface. Once the input molecule has been properly im-
ported, one of the two fingerprints ECFP4 or FCFP4 can
be chosen. The difference with respect to the first approach
to query iPPI-DB is that in this case the search is made on
all compounds of iPPI-DB regardless of the correspond-
ing PPI target. This can help the user to evaluate whether
its input structure can contain a scaffold that match more
than one PPI target and may therefore constitute either a
possible privileged substructure or a non-specific chemical
moiety. The chemical search provides the user with all the
binding data of the 20 closest iPPI-DB compounds to the
input structure according to the chosen type of fingerprint
and their Tanimoto index. It also recalls the structure of the
query compound along with its compliance with respect to
the three chemistry rules mentioned above (Figure 1).
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Figure 1. Example of a query on iPPI-DB using the mode ‘Chemical Similarity’. As the query compound, the user can either copy and paste a SMILES
string into the interface, or directly sketch the compound within a Marvin JS editor. Here, we show an example with the structure with a recently identified
piperidinone-based inhibitor of the MDM2/p53 interaction (25). Then, the compound can properly be imported, and the desired type of fingerprints for
the chemical similarity search has to be chosen between ECFP4 and FCFP4. The search provides the user with all the binding data (here 47) of the 20 most
similar iPPI-DB compounds in a table that can be sorted according to various criteria: molecular descriptors, activity, efficiencies or bibliographic IDs.
The interface also provides a summary of the properties of the input compound using a radar chart based on nine physicochemical properties (molecular
weight–MW, hydrophobicity–AlogP, the number of H-bond donors–HBD and acceptors–HBA, Topological Polar Surface Area–TPSA, the number of
rotatable bondsRB, the number of aromatic rings–Ar, the proportion of sp3 carbon atoms–Fsp3 and the number of chiral centers–R/S) and its compliance
to the three chemistry rules, Lipinski’s RO5, Veber’s and Pfizer’s 3/75.
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Figure 2. iPPI-DB ID card of compound 682. All data available of a given compound (here compound 682 as the first hit on the chemical similarity search
from Figure 1) are provided through four different tabs: compound summary, physicochemistry, pharmacology and drug similarity.
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Visualizing the results within a sortable and exportable
datasheet
The results of any query are displayed as a sortable and ex-
portable datasheet that contains all the binding data found
in iPPI-DB concerning the compounds fitting the query cri-
teria. Each line matches a compound’s binding data and re-
calls the iPPI-DB compound ID. Also displayed are a 2D
representation of the compound, a radar chart summariz-
ing the values of nine computed physicochemical descrip-
tors and the activity, the PPI target bound by the com-
pound (with a clickable link to the Uniprot (19) web server
(http://www.uniprot.org)), the name of the assay (with a
mouse over to have its full name) and whether it is a cellu-
lar assay, the type of activity that was derived from the as-
say (pIC50, pKi, etc.), the potency of the compound to bind
its target, the nine physicochemical descriptors, the ligand
and the lipophilic efficiencies (20), and the iPPI-DB ID of
the bibliographic source fromwhich the data were retrieved.
The icon indicates if it is a world patent or a research ar-
ticle. The link is clickable and redirects the user to either
the Wipo (www.wipo.int) or the Pubmed (21) web page. All
results can be exported as a CSV file that contains all the
above-mentioned data along with a Chemaxon canonical
SMILES of the compounds’ structures.
Accessing all data of a given iPPI-DB compound through its
ID card
If the user is interested in a particular modulator, a click
on its iPPI-DB ID within the results’ datasheet will open an
individual compound ID cardwhere all data about the com-
pound are summarized through four different tabs: com-
pound summary, physicochemistry, pharmacology and drug
similarity (Figure 2).
In the compound summary tab, the chemical structure of
the compound is recalled along with its canonical SMILES,
its IUPAC (http://www.iupac.org) name, brand name if any,
development phase if the compound is present in MDDR
march 2012 version), external links to the compound within
other databases such as PubChem (21) andChEMBL if any,
and a link to the Pubmed article or the Wipo patent with
the name of the compound as defined in the bibliographic
source to facilitate its identification within the document.
In the physicochemistry tab, the data provided give an es-
timation of the physicochemical profile of the compound.
This includes the compliance of the modulator with re-
spect to the three above mentioned physicochemistry rules:
Lipinkski’s RO5, Veber’s and Pfizer’s 3/75. But the user can
also consult a radar chart recalling the physicochemical pro-
file of the compound with respect to a hypothetical refer-
ence compound having the following properties:MW= 500
gmol−1, AlogP = 5, HBD = 5, HBA = 10, TPSA = 140,
RB = 10, Ar = 4, Fsp3 = 0.4 and R/S = 1. Those corre-
spond either to the limits of both the Lipinski’s RO5 and
Veber’s rule, or to the rule of thumb of Ritchie for the num-
ber of aromatic rings (15)–Ar, and the mean values usually
observed among drugs for Fsp3 and the number of chiral
centers–R/S. Finally, a principal component analysis indi-
vidual map is provided to locate the position (in red) in the
iPPI chemical space of the selected compound with respect
to all iPPI-DB compounds (in gray) and all the other iPPI-
DB compounds on the same target (in blue).
In the pharmacology tab, all binding data available on the
selected compound are given. A biplot also represents the
lipophilic- and ligand-efficiencies of the selected compound
(in red) with respect to the one of all iPPI-DB compounds
(in gray) and to the one of all the other modulators available
on the same target (in blue).
Finally in the drug similarity tab, the chemical structure
of the selected compounds is shown next to the five most
similar drugs that are found in theMDDRdatabase (march
2012 version). Along with their structures, the following
data are provided about the MDDR drugs: the Tanimoto
index (using FCFP4 fingerprint), the development phase
and the activity class (e.g. antineoplastic).
CONCLUSION
Given the importance taken by protein–protein interac-
tions in the last decade in the field of drug discovery, new
tools and data collections are necessary to address the chal-
lenge raised by this intricate class of therapeutic targets. In-
deed, one avenue to assist the identification of new chemi-
cal probes on PPI is to collect successful examples of such
modulators and learn from these molecules. With the iPPI-
DB initiative, we hope that the presence in one database of
manually annotated data with freely accessible and intuitive
tools to query them will boost drug discovery and chemical
biology projects for this target class. Along the same line,
big data analysis of such databases and of databases con-
taining regular compounds should help to rationalize why
some compounds are capable of modulating PPI interfaces
(22). We plan to proceed to regular updates of the data as
the number of inhibitors available is constantly rising. To
this end, by the end of the year we anticipate to add around
300 new compounds on about 20 new PPI targets. The ad-
dition of new inhibitors and new targets is key to have a
representative subset of both the PPI chemical and target
spaces. In addition, we will also implement stabilizers of
protein–protein interactions as they represent a new era of
PPI modulation that also needs to be addressed. Hopefully,
our iPPI-DB initiative together with, for instance, the free
online physical chemistry-toxicophore-PAINS filtering tool
(23) and structure-based virtual screening server (24), will
help biologists, chemists and clinicians in their attempt to
discover new drugs and chemical probes for this challeng-
ing target class.
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